Why Ophthalmology?

Why Ophthalmology?

The ophthalmology industry is projected to rise at a 11% CAGR to $57 billion in 2020 (from $37 billion in 2015). With an increasing number of surgical procedures and drug treatments along with rising prices, investing in the industry provides a large opportunity. In the last five years, over 34 ophthalmic companies were acquired for an aggregate total of $17 billion with over 60% of these companies being venture backed.
The ophthalmology industry is projected to rise at a 11% CAGR to $57 billion in 2020 (from $37 billion in 2015). With an increasing number of surgical procedures and drug treatments along with rising prices, investing in the industry provides a large opportunity. In the last five years, over 34 ophthalmic companies were acquired for an aggregate total of $17 billion with over 60% of these companies being venture backed.
With significant unmet medical needs, breakthrough technologies on the horizon, a clear path to exit for superior products, acquisitive strategic companies with nearly $1 trillion in firepower, and strong barriers to entry—Ophthalmology is a proven market for venture capital.
With significant unmet medical needs, breakthrough technologies on the horizon, a clear path to exit for superior products, acquisitive strategic companies with nearly $1 trillion in firepower, and strong barriers to entry—Ophthalmology is a proven market for venture capital.

Our Strategy

The objective of the Fund is to utilize our location and information advantage through our KOL partnerships to achieve exceptional financial returns while also creating societal benefits by being a lead investor in the most promising late- and growth-stage ophthalmic companies from around the globe including both devices and drugs.

Economic objective

(exceptional financial returns)

The primary focus of the Fund is to achieve exceptional financial returns through a disciplined investing approaching as exhibited in Fund I.  Investments are made with the goal of reaching realizations in two to four years after the first investment in a company.

Location

We are perfectly positioned with the Visionary fund being located in Orange County, California, the global headquarters of Ophthalmology. This area provides access to a rich pool of businesses in both scientific and medical fields that serves as the hub of major innovation in ophthalmology. With over 80 ophthalmology companies in Orange County alone that contribute $12.5 billion to the local economy, it truly is the place to be for a unique advantage.

Companies in Visionary Ventures’ Portfolio that Have Large Scale Social Impact

Social Objective

(societal benefits)

Through investments in companies that are addressing large unmet or underserved markets in ophthalmology, Visionary Ventures is able to have a significant impact on improving people’s lives globally by improving their vision and helping to eliminate blindness through access to new treatments and lower cost treatments.

Information advantage

A domain expertise in ophthalmology is possible through the access to KOLs as our investor partners and industry experts in Orange County and across the globe. There are over 40 KOL’s participating in the fund that are the best in their fields ranging from doctors and specialists in both anterior and retina. Given their exceptional status and years of experience, they are the best partners to give access to high quality deal flow as well as aiding in the due diligence process and the ongoing management of potential investments.

Lead investor

We help company management address the major issues necessary to commercialize and partner with Strategics through a seasoned investment committee, comprised of a number of highly respected ophthalmology investors and business leaders who have deep involvement in investing in ophthalmology and private equity.
Through this process, Visionary has built a successful and attractive portfolio.

We are constantly looking for companies and entrepreneurs with real vision that are addressing a large unmet market and that are open to partnerships and opportunities with those who believe in disruptive and impactful innovation.